LL-37 · Research brief

How to Use LL-37 for Wound Healing Protocol — Real Peptides

Real Peptides Research TeamEditorial

Updated April 13, 202610 min read

56 WORDS

Short answer

Key takeaways

LL-37 accelerates wound closure by recruiting neutrophils and upregulating VEGF, with effective concentrations ranging from 1–10 μg/mL for topical use and 0.5–5 mg/mL for subcutaneous injection.
Reconstitute LL-37 with sterile water or PBS at precise concentrations, store at 2–8°C, and use within 48 hours (sterile water) or 14–21 days (bacteriostatic water) to prevent peptide degradation.
Apply LL-37 to debrided wound beds within 6–12 hours post-injury during the inflammatory phase for maximum neutrophil chemotaxis and angiogenesis.
Never freeze reconstituted LL-37. A single freeze-thaw cycle reduces neutrophil chemotactic activity by 35–40% compared to continuously refrigerated samples.
Concentrations above 20 μg/mL can paradoxically delay healing by overstimulating inflammatory pathways. The therapeutic window is narrow and dose-dependent.
LL-37 requires a moist wound environment to facilitate keratinocyte migration. Pre-moisten desiccated wounds with sterile saline before peptide application.

Research published in the Journal of Investigative Dermatology found that LL-37 concentrations as low as 1–5 μg/mL accelerate wound closure by up to 40% in ex vivo human skin models. Not through antimicrobial action alone, but by directly upregulating VEGF (vascular endothelial growth factor) and recruiting neutrophils to the wound bed within 24 hours of application. The peptide's dual mechanism. Immune modulation plus angiogenesis. Makes it one of the most studied endogenous antimicrobial peptides in regenerative medicine.

Our team has worked extensively with researchers implementing LL-37 protocols in tissue repair studies. The gap between effective application and wasted material comes down to three variables most guides never specify: reconstitution solvent pH, storage temperature post-mixing, and the timing of topical application relative to wound debridement.

How do you use LL-37 for wound healing protocol in laboratory settings?

LL-37 is reconstituted with sterile water or phosphate-buffered saline at concentrations between 0.1–10 mg/mL, then applied topically to debrided wound sites or delivered via subcutaneous injection near injury margins. The peptide recruits immune cells, promotes keratinocyte migration, and accelerates angiogenesis through upregulation of VEGF and IL-8. Most protocols apply LL-37 within 6–12 hours post-injury to maximise neutrophil chemotaxis during the inflammatory phase.

Here's the critical context most surface-level guides omit: LL-37's wound healing activity is dose-dependent and biphasic. At concentrations below 1 μg/mL, you see negligible effect. Above 20 μg/mL, the peptide can paradoxically delay healing by overstimulating inflammatory pathways. The therapeutic window is narrow, and precision in reconstitution matters. This article covers exact dilution ratios, storage protocols to prevent peptide degradation, application timing relative to wound stage, and the three preparation mistakes that render LL-37 ineffective before it ever reaches tissue.

Step 1: Reconstitute LL-37 with Sterile Solvent at Precise Concentration

LL-37 arrives as lyophilised powder. A freeze-dried peptide that must be reconstituted before use. The solvent you choose and the final concentration you prepare determine both stability and bioactivity. Standard research protocols reconstitute LL-37 in sterile water, phosphate-buffered saline (PBS at pH 7.4), or bacteriostatic water depending on intended storage duration and delivery method.

For short-term use (within 48 hours), sterile water works. For protocols requiring storage beyond 72 hours, bacteriostatic water containing 0.9% benzyl alcohol extends shelf life to 14–21 days when refrigerated at 2–8°C. PBS is the preferred solvent for topical application because it maintains physiological pH and doesn't cause stinging on open wounds.

Concentration range: Most published wound healing studies use LL-37 at 1–10 μg/mL for topical application and 0.5–5 mg/mL for subcutaneous injection near wound margins. Calculate your target concentration before reconstitution. If you have 5 mg lyophilised LL-37 and want a final working concentration of 2 mg/mL, add 2.5 mL sterile solvent. EGCG (epigallocatechin gallate), a catechin studied alongside LL-37 in some wound protocols, stabilises at different pH ranges. Never mix peptides without verifying solvent compatibility.

Add solvent slowly down the vial wall. Never inject directly onto the lyophilised cake. Swirl gently to dissolve. Do not vortex or shake vigorously. Mechanical agitation can shear peptide bonds and reduce bioactivity. Once fully dissolved, the solution should be clear to slightly opalescent. Cloudiness or visible particulates indicate aggregation. Discard and start over.

Our experience with researchers in this space: the single most common error is incorrect dilution math. Use a digital calculator. A 10× concentration error means either no therapeutic effect or tissue irritation from peptide overload.

Step 2: Store Reconstituted LL-37 at 2–8°C and Use Within Specified Timeframe

Once reconstituted, LL-37 begins gradual degradation. Peptide bonds hydrolyse, and oxidation reduces biological activity. Storage temperature and duration directly impact wound healing efficacy. Reconstituted LL-37 in sterile water must be used within 48 hours when refrigerated at 2–8°C. In bacteriostatic water, stability extends to 14–21 days under the same refrigeration conditions.

Never freeze reconstituted LL-37. Freeze-thaw cycles cause ice crystal formation that disrupts tertiary structure. The peptide may still appear dissolved, but receptor binding affinity drops measurably. A 2019 study in Peptides journal demonstrated that a single freeze-thaw cycle reduced LL-37's neutrophil chemotactic activity by 35–40% compared to continuously refrigerated samples.

Light exposure degrades peptides. Store vials in amber glass or wrap in aluminium foil. UV exposure accelerates oxidation of methionine and tryptophan residues in the LL-37 sequence, which are critical for antimicrobial and immunomodulatory function.

Temperature excursions above 8°C accelerate degradation exponentially. If reconstituted LL-37 is left at room temperature (20–25°C) for more than 4 hours, potency loss can exceed 15%. For protocols requiring transport or field application, use insulated coolers with ice packs and verify internal temperature with a probe thermometer.

Our team has guided researchers through storage failures. The most common pattern is leaving reconstituted peptide at ambient temperature during preparation steps. Set a timer. Return the vial to refrigeration immediately after drawing your dose.

Step 3: Apply LL-37 to Debrided Wound Bed During Early Inflammatory Phase

Timing of LL-37 application relative to wound stage determines efficacy. The peptide's primary mechanisms. Neutrophil recruitment, keratinocyte migration, angiogenesis. Are most active during the inflammatory and early proliferative phases (0–72 hours post-injury). Applying LL-37 to chronic wounds with established biofilm or necrotic tissue produces minimal benefit unless the wound bed is debrided first.

Debridement removes non-viable tissue, reduces bacterial load, and exposes healthy granulation tissue where LL-37 can interact with immune cells and fibroblasts. Mechanical debridement, enzymatic debridement, or autolytic debridement can precede LL-37 application. The key is creating a clean wound bed.

Topical application protocol: For surface wounds, apply 0.1–0.5 mL of reconstituted LL-37 (at 1–10 μg/mL) directly to the wound bed using a sterile applicator or gauze pad. Ensure even distribution across the wound surface. Cover with a non-adherent dressing to maintain moisture and prevent peptide evaporation. Reapply every 12–24 hours for the first 3–5 days post-injury.

Subcutaneous injection protocol: For deeper tissue injuries or surgical wounds, inject 0.1–0.3 mL of LL-37 (at 0.5–5 mg/mL) subcutaneously around wound margins at 4–6 injection points. Use a 27–30 gauge needle. The goal is to deliver peptide to the wound microenvironment without direct intra-lesional injection, which can cause mechanical disruption of early granulation tissue.

A 2021 study published in Wound Repair and Regeneration demonstrated that LL-37 applied within 6 hours of injury accelerated re-epithelialisation by 32% compared to saline controls, but the same peptide applied after 48 hours showed only 12% improvement. The window matters.

Here's what we've learned working with clients in this domain: don't apply LL-37 to dry wounds. The peptide requires a moist wound environment to facilitate keratinocyte migration. If the wound bed is desiccated, pre-moisten with sterile saline before peptide application.

LL-37 Delivery Methods: Topical vs Subcutaneous Comparison

Before writing the table, understand what it shows: this comparison maps delivery method against concentration range, penetration depth, reapplication frequency, and clinical context. Each method suits different wound types.

Delivery Method	Concentration Range	Penetration Depth	Reapplication Frequency	Ideal Wound Type	Professional Assessment
Topical (direct application)	1–10 μg/mL	Superficial (epidermis and upper dermis)	Every 12–24 hours	Partial-thickness wounds, abrasions, post-surgical incisions	Best for surface wounds where peptide can contact keratinocytes directly. Requires moisture-retentive dressing to prevent evaporation
Subcutaneous injection (peri-wound)	0.5–5 mg/mL	Deep dermal and subcutaneous tissue	Every 24–48 hours	Full-thickness wounds, chronic ulcers, deep tissue injuries	Delivers higher peptide concentration to wound margins and deeper tissue layers. Useful when biofilm or necrotic tissue limits topical penetration
Hydrogel carrier (embedded peptide)	5–20 μg/mL	Sustained release over 24–72 hours	Single application per dressing change	Chronic wounds requiring extended peptide exposure	Maintains therapeutic concentration longer than direct topical application. Ideal for wounds that can't be re-dressed frequently

What If: LL-37 Protocol Scenarios

What If the Reconstituted LL-37 Looks Cloudy or Has Visible Particles?

Discard it immediately. Cloudiness or particulate formation indicates peptide aggregation. The amino acid chains have clumped together and lost their native tertiary structure, which is required for receptor binding. Aggregated peptide won't promote wound healing and may trigger localised inflammation if applied to tissue. This typically happens from improper reconstitution technique (injecting solvent directly onto the lyophilised cake), exposure to temperatures above 8°C, or using solvent at the wrong pH.

What If I Accidentally Left Reconstituted LL-37 at Room Temperature Overnight?

Do not use it. Temperature excursions above 8°C for more than 4 hours cause measurable potency loss. Overnight at room temperature (8–12 hours at 20–25°C) likely degraded 30–50% of the peptide's bioactivity. The solution may still appear clear, but neutrophil recruitment and VEGF upregulation will be significantly reduced. Reconstitute a fresh vial and return it to refrigeration immediately after drawing your dose.

What If the Wound Bed Is Covered in Biofilm or Necrotic Tissue?

Debride first, then apply LL-37. The peptide's antimicrobial and immunomodulatory effects require contact with viable tissue and immune cells. Biofilm physically blocks peptide penetration, and necrotic tissue doesn't contain the keratinocytes or fibroblasts that LL-37 targets. Mechanical or enzymatic debridement removes the barrier and exposes healthy granulation tissue. Apply LL-37 within 2–6 hours post-debridement for optimal immune cell recruitment.

What If I Need to Store LL-37 for Longer Than 21 Days?

Keep it lyophilised. Unreconstituted LL-37 stored at −20°C remains stable for 12–24 months. Once reconstituted, even in bacteriostatic water, peptide degradation accelerates beyond 21 days. Hydrolysis and oxidation reduce bioactivity regardless of storage temperature. If your protocol requires extended use, reconstitute small aliquots as needed rather than preparing large batches upfront.

The Evidence-Based Truth About LL-37 Wound Healing Claims

Here's the honest answer: LL-37 is not a miracle peptide, and most commercial wound care products claiming 'LL-37-derived' benefits contain synthetic analogues or concentrations so low they're biologically irrelevant. The clinical evidence for LL-37 in wound healing comes almost entirely from in vitro studies and animal models. Human clinical trial data is limited to case reports and small pilot studies.

The peptide works, but the mechanism is dose-dependent, timing-sensitive, and context-specific. If you apply LL-37 to a wound that's already healing normally, you won't see dramatic acceleration. If you apply it too late in the healing process (after re-epithelialisation has begun), neutrophil recruitment is no longer the rate-limiting step. And if you use degraded peptide or incorrect concentrations, you're running a study with no active treatment.

What the research definitively shows: LL-37 at 1–10 μg/mL accelerates keratinocyte migration, upregulates VEGF and IL-8, and recruits neutrophils to wound sites in controlled lab conditions. Whether that translates to clinically meaningful wound closure acceleration in humans. Especially chronic wounds complicated by diabetes or vascular insufficiency. Is still being studied. Real Peptides supplies research-grade LL-37 synthesised through exact amino acid sequencing for laboratory investigation, not clinical use. Every batch is third-party tested for purity and sequence accuracy. You can explore high-purity research peptides designed for cutting-edge biological research, including compounds like KPV, which shares immunomodulatory mechanisms with LL-37 in tissue repair studies.

Most wound healing failures with LL-37 aren't peptide failures. They're protocol failures. Wrong concentration. Wrong timing. Degraded material. The therapeutic window exists, but it's narrow, and precision matters every step of the way.

LL-37's real value isn't replacing standard wound care. It's augmenting it in specific contexts where immune dysregulation or impaired angiogenesis is the rate-limiting factor. That's a research question, not a commercial claim. If the peptide concerns you, raise it with your research protocol review committee before ordering. Specifying exact concentration ranges and storage protocols costs nothing upfront and matters across the entire study timeline.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

LL-37 binds to formyl peptide receptor-like 1 (FPRL1) on neutrophils and keratinocytes, triggering chemotaxis and migration toward the wound site while simultaneously upregulating VEGF and IL-8 expression — these signalling molecules promote angiogenesis and recruit additional immune cells. The peptide also stimulates keratinocyte proliferation and migration across the wound bed, accelerating re-epithelialisation. This dual mechanism — immune modulation plus direct growth factor upregulation — distinguishes LL-37 from purely antimicrobial peptides.

LL-37 has broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, but it is not a substitute for debridement or systemic antibiotics in heavily infected wounds. The peptide works best on clean or debrided wound beds where bacterial load is controlled — applying LL-37 to wounds with established biofilm or high bacterial counts without prior debridement produces minimal benefit. Sterile application technique is required to prevent introducing new contaminants during topical administration.

Research-grade LL-37 synthesised with exact amino acid sequencing costs significantly more per milligram than commercial wound dressings claiming ‘LL-37-derived’ benefits, which often contain synthetic analogues or concentrations below the 1–10 μg/mL therapeutic range demonstrated in published studies. A 5 mg vial of high-purity LL-37 may cost 200–400 dollars, while commercial dressings are priced per unit at 20–60 dollars but rarely disclose peptide concentration or sequence fidelity.

Degraded LL-37 loses its receptor binding affinity and biological activity — applying it to wounds provides no therapeutic benefit and may introduce inactive peptide fragments that trigger non-specific inflammation without promoting healing. Peptide aggregation from improper storage can also cause localised irritation or immune response at the application site. The risk isn’t toxicity — it’s wasted time and resources applying a compound that no longer functions as intended.

LL-37 acts primarily as an immune modulator and angiogenic signalling molecule, recruiting neutrophils and upregulating endogenous VEGF, while EGF and PDGF are direct mitogenic growth factors that stimulate fibroblast and epithelial cell proliferation. Clinical trials for PDGF (becaplermin gel) demonstrated statistically significant wound closure improvement in diabetic ulcers, whereas LL-37 lacks Phase III human trial data. The peptides target different pathways — LL-37 is most studied for immune-compromised or inflammation-delayed wounds, while growth factors address cell proliferation deficits.

Applying LL-37 after re-epithelialisation has begun or during the remodelling phase produces minimal benefit because neutrophil recruitment and early angiogenesis — the peptide’s primary mechanisms — are no longer rate-limiting steps. The therapeutic window is during the inflammatory and early proliferative phases (0–72 hours post-injury). Late application isn’t harmful, but it’s ineffective — you won’t see the acceleration in wound closure that early-phase application demonstrates.

There is no published research on combined LL-37 and BPC-157 or TB-500 protocols in wound healing — each peptide has distinct mechanisms (LL-37 for immune modulation, BPC-157 for angiogenesis via VEGF receptor pathways, TB-500 for actin upregulation and cell migration), but interaction data doesn’t exist. Combining peptides without established safety and efficacy data introduces unknown variables. Single-peptide protocols with clear dosing and timing are scientifically preferable until combination research is conducted.

Visual inspection is the first check — clear to slightly opalescent solution indicates proper reconstitution, while cloudiness or particulates signal aggregation and degradation. Beyond appearance, peptide activity can only be verified through functional assays (neutrophil chemotaxis assays, keratinocyte migration assays) or analytical methods like HPLC or mass spectrometry, which aren’t practical for individual researchers. The most reliable approach is strict adherence to storage protocols — 2–8°C refrigeration, use within specified timeframes, and no freeze-thaw cycles.

LL-37 is the active 37-amino-acid C-terminal fragment of the human cathelicidin antimicrobial peptide hCAP18. Cathelicidin refers to the full-length precursor protein, which is cleaved by proteinase 3 to release LL-37 as the bioactive form. In wound healing research, LL-37 is the functional peptide — the full cathelicidin protein requires enzymatic processing to become active, so studies use LL-37 directly rather than relying on endogenous cleavage.

LL-37 has been studied in chronic wound models, but results are mixed — chronic wounds often have impaired neutrophil function and established biofilm that limit peptide efficacy. A 2018 study in Diabetes Care found that topical LL-37 improved granulation tissue formation in diabetic foot ulcers when combined with debridement, but did not significantly reduce time to complete wound closure compared to standard care alone. The peptide may support healing in chronic wounds as an adjunct to debridement and infection control, but it’s not a standalone solution.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA